John Paulson

John Paulson is a declared insider at 5 companies (board member); the most frequent names are Bausch Health Companies Inc., Bausch & Lomb Corp and Valeant Pharmaceuticals International, Inc. We count 96 filings; the first trade dates from 30 June 2017 and the latest from 30 September 2026.

On the open market, the record shows 24 purchases worth €674.3M and 3 sales worth €98.0M. Netting one side against the other leaves €576.3M of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 66 share grants and 3 option exercises.

Half of the purchases are above €6.4M and half below. 1 out of 22 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 20 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 80% of cases, with a median move of +9.2%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 2 October 2026, the filings show a share grant worth €55k in Bausch Health Companies Inc. The last insider purchase was made public on 14 August 2025, 435 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.